- About us
- Our people
- Portfolio
- Sustainability
- News and Insights
- Investors
- Contact
Our purpose is to invest to extend and enhance human life
Watch video
Our team members are experts at what they do
Our people
A differentiated and diversified portfolio of life science companies
Portfolio
To unlock the potential from truly innovative science to transform patients’ lives
We create, build and scale companies around exceptional science to create a diversified portfolio of 20-25 globally leading healthcare businesses
Syncona domain expertise
Our deep expertise in four key modalities enables the rapid translation of scientific research into companies with the potential to be global leaders and the development of a diversified portfolio of 20-25 companies
Making a positive contribution
We are committed to managing our business in a sustainable way, investing responsibly, and supporting our portfolio companies in making positive contributions to society by developing treatments that will make a difference to the lives of patients and their families.
Latest videos
Scaling for growth
| Video length 09:28
Ed Hodgkin and Magdalena Jonikas discuss OMass Series B
| Video length 7:43
Syncona CEO Martin Murphy discusses Clade Series A financing
| Video length 10:16
Anaveon doses first patient
| Video length 6:18
Introduction to Richard Francis, Chief Executive of Purespring Therapeutics
| Video length 3:42
Introduction from Quell Therapeutics, CEO, Iain McGill
| Video length 5:38
Quell: the science and the unmet medical need for patients
| Video length 5:25
Syncona’s Martin Murphy and Freddie Dear: Quell Series A expansion
| Video length 4:25
Introducing Resolution Therapeutics
| Video length 11:28
Introduction to Purespring
| Video length 5:47
Syncona FY20: Martin Murphy discusses FY20 results
| Video length 6:15
Syncona FY20: Martin Murphy discusses the impact of COVID-19
| Video length 4:52
Syncona FY20: Martin Murphy discusses the outlook for Syncona
| Video length 2:53
Achilles doses first patient
| Video length 1:40
Gene Therapy explained
| Video length 3:11
Building Syncona’s Gene Therapy platform
| Video length 7:02
An introduction to Gene Therapy
| Video length 4:45
Quell Therapeutics and an emerging area of cell therapy
| Video length 7:56
Latest insights
Annual Report and Accounts 2022
Our Annual Report and Accounts 2022 provides an overview of our most recent financial year, as we look to deliver on behalf of our stakeholders.
30.06.22 |
pdf (7.22Mb)
Download
An expert multi-disciplinary team, attracting world-class talent
We are differentiated by our people, who identify innovative technology and take a commercial approach to building businesses capable of delivering transformational treatments to patients.
Leadership key facts*
12
Members of the investment team
170
Years of life science and investment expertise
92%
Investment team with PhDs or M.D.s
*All as of 31 December 2022